Israeli startup AccuLine has successfully completed a Seed funding round, raising $4.2 million with the backing of eHealth Ventures and Maccabi Healthcare Services. This investment will facilitate the ongoing development and commercialization of their innovative system, CORA, which is designed for the early detection of coronary artery disease (CAD).
Company Background and Founding Team
Founded in early 2022, AccuLine is led by a team of four: CEO Moshe Barel, Prof. Aharon Frimerman, head of Interventional Cardiology at Hillel Yaffe Medical Center, Prof. Shai Revzen from the University of Michigan’s computer science department, and CTO Benny Shani. Currently, the company operates with a small team of seven based in Petah Tikva and has raised a total of $5.5 million to date.
Addressing a Critical Health Challenge
AccuLine’s solution targets a significant unmet need in the medical field. Heart attacks remain the leading cause of death globally, yet existing diagnostic tools for early CAD detection are often limited. Traditional stress ECG tests lack the necessary accuracy, while more invasive procedures like cardiac CT or coronary angiography involve higher costs, radiation exposure, and long wait times. Moreover, these invasive tests are typically only available to symptomatic or high-risk patients.
The CORA System: A Game-Changer in Diagnostics
AccuLine’s CORA system provides a rapid and straightforward testing solution that can be conducted in a family doctor’s office by any medical personnel. In just a few minutes, CORA analyzes three biological signals: the heart’s electrical activity, oxygen saturation, and breathing phase. Utilizing advanced signal filtering and deep learning algorithms, the system evaluates the condition of the patient’s coronary arteries, guiding appropriate treatment options.
Moshe Barel emphasises the value of this non-invasive testing method: “Diagnosing patients at very early stages of risk for CAD without invasive testing will add value to patients, healthcare systems, doctors, and insurance organisations.”
Market Potential and Future Outlook
The U.S. market for this technology is estimated to be worth $7 billion annually, with AccuLine projecting sales in the hundreds of millions of dollars post-launch. The potential impact of this technology extends beyond individual patients; it could significantly reduce healthcare costs associated with unnecessary tests and post-heart attack treatments.
Clinical Validation and Future Studies
AccuLine has recently completed a clinical study across seven medical centres in Israel, including Ichilov and Hillel Yaffe, involving 300 participants who underwent coronary angiography to validate the CORA system’s diagnostic capabilities. Previous studies have already shown promising results, successfully diagnosing significant coronary artery disease in participants. A third clinical study is planned for next year in the U.S. to secure FDA approval.
AccuLine’s innovative approach is poised to transform how coronary artery disease is detected, potentially saving millions of lives and substantially reducing healthcare costs.
